Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008;14:1159–66.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007;18:1943–50.
   PubMed Web of Science ®Google Scholar
• Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: Systematic review of current results. J Cancer Res Clin Oncol 2009;135:1637–1645.
   PubMed Web of Science ®Google Scholar
• Loggie BW, Sterchi JM, Rogers AT, Lentz S, Holmesley H, Charles D, Sundberg D. Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers, Reg Cancer Treat 1995;7:78–81.
   Google Scholar
• Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219–28.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254–61.
   PubMedGoogle Scholar
• Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 2009;15:216–24.
   PubMed Web of Science ®Google Scholar
• El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117–27.
   PubMed Web of Science ®Google Scholar
• Stewart JH IV, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Current status and future directions. Ann Surg Oncol 2005;12:765–77.
   PubMed Web of Science ®Google Scholar
• AJCC. Ovary and primary peritoneal carcinoma. In: AJCC cancer staging handbook, 7th ed. Springer; 2009. pp 501–6.
   Google Scholar
• Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009;14:683–94.
   PubMed Web of Science ®Google Scholar
• Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, Stewart JH, Levine EA. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years: survival benefit at considerable morbidity and mortality. Ann Surg Oncol 2013. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/
   Google Scholar
• Cascales-Campos P, Gil J, Gil E, Feliciangeli E, López V, Gonzalez AG, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC–IV ovarian cancer. Critical analysis in elderly patients. Eur J Obstet Gynecol Reprod Biol 2014;179:88–93.
   PubMed Web of Science ®Google Scholar
• Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2015;22:1708–15.
   PubMed Web of Science ®Google Scholar
• Razzouk-Cadet M, Zwarthoed C, Desantis M, Viau P, Mahamat A, Mounier N, et al. Diagnostic value of FDG-PET/CT for peritoneal carcinomatosis (PC) before hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Clin Oncol 2012;30(Suppl):e15574.
   Google Scholar
• Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. Gynecol Oncol 2014;132:303–6.
   PubMed Web of Science ®Google Scholar
• Gilly FN, Carry PY, Sayag AC. Regional chemotherapy with mitomycin C and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124–9.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor Peritoneal carcinomatosis: Principles of management. Boston, MA: Kluwer Academic Publishers; 1996. pp 359–74.
   Google Scholar
• Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2014;28:697–720.
   PubMed Web of Science ®Google Scholar
• Perez CA, Mutic S. Advances and future of radiation oncology. Rep Pract Oncol Radiother 2013;18:329–32.
   PubMedGoogle Scholar
• Isa N. Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother 2013;19:259–66.
   PubMedGoogle Scholar
• Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S. Genomic profile of ovarian carcinomas. BMC Cancer 2014;14:315.
   PubMed Web of Science ®Google Scholar
• Polom W, Markuszewski M, Rho YS, Matuszewski M. Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2. Cent Eur J Urol 2014;67:310–13.
   PubMedGoogle Scholar
• de Boer E, Harlaar NJ, Taruttis A, Nagengast WB, Rosenthal EL, Ntziachristos V, van Dam GM. Optical innovations in surgery. Br J Surg 2015;102:e56–72.
   PubMed Web of Science ®Google Scholar
• Polom W, Markuszewski M, Rho YS, Matuszewski M. Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1. Cent Eur J Urol 2014;67:142–8.
   PubMedGoogle Scholar
• Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Löwik CW, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011;104:323–32.
   PubMed Web of Science ®Google Scholar
• Murawa D, Polom K, Rho YS, Murawa P. Developments in near-infrared-guided hepatobiliary, pancreatic and other upper gastrointestinal surgery. Contrast Media Mol Imaging 2013;8:211–19.
   PubMed Web of Science ®Google Scholar
• Polom K, Murawa D, Nowaczyk P, Rho YS, Murawa P. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green – human serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol 2012;38:137–42.
   PubMed Web of Science ®Google Scholar
• Mitsumori N, Nimura H, Takahashi N, Kawamura M, Aoki H, Shida A, et al. Sentinel lymph node navigation surgery for early stage gastric cancer. World J Gastroenterol 2014;20:5685–93.
   PubMed Web of Science ®Google Scholar
• Polom K, Murawa D, Rho YS, Spychala A, Murawa P. Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. Br J Dermatol 2012;166:682–3.
   PubMed Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med 2011;17:1315–19.
   PubMed Web of Science ®Google Scholar
• van Oosten M, Crane LM, Bart J, van Leeuwen FW, van Dam GM. Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): A novel target identification tool. Transl Oncol 2011;4:71–82.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Mitsunaga M, Longmire MR, Choyke PL, Kobayashi H. Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. Int J Cancer 2011;129:1671–7.
   PubMed Web of Science ®Google Scholar
• Kishi K, Fujiwara Y, Yano M, Motoori M, Sugimura K, Ohue M, et al. Diagnostic laparoscopy with 5-aminolevulinic-acid-mediated photodynamic diagnosis enhances the detection of peritoneal micrometastases in advanced gastric cancer. Oncology 2014;87:257–65.
   PubMed Web of Science ®Google Scholar
• Liu Y, Endo Y, Fujita T, Ishibashi H, Nishioka T, Canbay E, et al. Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: Results of a phase I trial. Ann Surg Oncol 2014;21:4256–62.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248–59.
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26–31.
   PubMed Web of Science ®Google Scholar
• Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract 2012;2012:541842.
   PubMed Web of Science ®Google Scholar
• Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004;94:325–32.
   PubMed Web of Science ®Google Scholar
• Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006;32:671–5.
   PubMed Web of Science ®Google Scholar
• Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35–41.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 2015;22:987–93.
   PubMed Web of Science ®Google Scholar
• Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients – a case-control study. J Surg Oncol 2014;110:661–5.
   PubMed Web of Science ®Google Scholar
• Koga S, Hamazoe R, Maeta M. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with anticancer drugs. Cancer Res 1984;44:1840–2.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Shrestha RD, Kokubun M. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seedings. Ann Surg 1988;208:36–41.
   PubMed Web of Science ®Google Scholar
• Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–19.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–63.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 2009;249:900–7.
   PubMed Web of Science ®Google Scholar
• Fagotti A, B. Costantini, G. Vizzielli, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 2011;122:221–5.
   PubMed Web of Science ®Google Scholar
• Königsrainer I, Horvath P, Struller F, Grischke EM, Wallwiener D, Königsrainer A, Beckert S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: A single centre experience. Langenbecks Arch Surg 2014;399:589–94.
   PubMed Web of Science ®Google Scholar
• Macrì A, Arcoraci V, Belgrano V, Caldana M, Cioppa T, Costantini B, et al. Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: preliminary analysis of a multicentre study. Anticancer Res 2014;34:5689–93.
   PubMed Web of Science ®Google Scholar
• Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol 2015;41:1578–89.
   PubMed Web of Science ®Google Scholar
• Warschkow R, Tarantino I, Lange J, Müller SA, Schmied BM, Zünd M, Steffen T. Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg 2012;6:12.
   PubMedGoogle Scholar
• Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2012;22:778–85.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients Eur J Surg Oncol 2013;39:1435–43.
   PubMed Web of Science ®Google Scholar
• Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer 2010;97:E23–32.
   PubMedGoogle Scholar
• Cascales Campos PA, Gil Martínez J, Galindo Fernández PJ, Gil Gómez E, Martínez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol 2011;37:543–8.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol 2014;21:2383–9.
   PubMed Web of Science ®Google Scholar
• Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: A multicenter prospective observational study. J Gynecol Oncol 2015;26:54–61.
   PubMed Web of Science ®Google Scholar
• Deraco M, Kusomura S, Virzi S, Puccio F, Macrì A, Famulari C, et al. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy as upfront therapy for advanced EOC: Multi-institutional phase II study. Gynecol Oncol 2011;122:215–20.
   PubMed Web of Science ®Google Scholar
• Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113:315–25.
   PubMed Web of Science ®Google Scholar
• Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J Surg Oncol 2011;103:10–16.
   PubMed Web of Science ®Google Scholar
• Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, et al. HIPEC in ovarian cancer: first report of HYPER-O registry. Int J Gynecol Cancer 2010;20:61–9.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 2010;101:149–55.
   PubMed Web of Science ®Google Scholar
• Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 2009;16:993–1000.
   PubMed Web of Science ®Google Scholar
• Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer – 12-year single center experience. Eur J Surg Oncol 2009;35:1186–91.
   PubMed Web of Science ®Google Scholar
• Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 2010;36:589–93.
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Mendivil AA, Abaid LN, Brown Iii JV, Wilcox AM, Goldstein BH. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperthermia 2015;31:8–14.
   PubMed Web of Science ®Google Scholar
• Roviello F, Pinto E, Corso G, Pedrazzani C, Caruso S, Filippeschi M, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol 2010;102:663–70.
   PubMed Web of Science ®Google Scholar
• Rufian S, Munoz-Casares FC, Briceno J, Díaz CJ, Rubio MJ, Ortega R, et al. Radical surgery – peritonectomy and intra-operative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006;94:316–24.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02124421
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01091636
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01628380
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02328716
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01709487
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02249013
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02199171
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02217956
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02567253
   Google Scholar
• Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, et al. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: A pilot study. Gynecol Oncol 2013;129:81–5.
   PubMed Web of Science ®Google Scholar
• Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007;106:193–200.
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 2012;19:2352–9.
   PubMed Web of Science ®Google Scholar
• Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J Surg 2007;31:1813–20.
   PubMed Web of Science ®Google Scholar
• de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003;23:3019–27.
   PubMed Web of Science ®Google Scholar
• Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: A multi-institutional study. BJOG 2012;119:800–9.
   PubMed Web of Science ®Google Scholar
• Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, Felci N. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005;15:233–9.
   PubMed Web of Science ®Google Scholar
• Helm CW, Randall-Whitis L, Martin RS III, Metzinger DS, Gordinier ME, Parker LP, Edwards RP. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007;105:90–6.
   PubMed Web of Science ®Google Scholar
• Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: A multi-institutional case control study. Ann Surg Oncol 2014;21:3621–7.
   PubMed Web of Science ®Google Scholar
• Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 2009;11:753–9.
   PubMed Web of Science ®Google Scholar
• Massari R, Barone M, Basilico R, Carella C, Colasante A, De Tursi M, et al. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent epithelial ovarian cancer: A single center cohort study. Minerva Chir 2014;69:17–26.
   PubMed Web of Science ®Google Scholar
• Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004;2:21.
   PubMedGoogle Scholar
• Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, et al. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Minerva Chir 2014;69:27–35.
   PubMed Web of Science ®Google Scholar
• Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004;28:1040–5.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT00426257
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01539785
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01767675
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01376752
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01970722
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT01588964
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02217956
   Google Scholar
• www.clinicaltrials.gov/ct2/show/NCT02567253
   Google Scholar
• Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study. Ann Surg Oncol 2014;22:570–5.
   Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248–59.
   PubMed Web of Science ®Google Scholar
• Verleye L, Ottevanger PB, Vergote I. Surgical program building in advanced ovarian cancer: European perspective. Gynecol Oncol 2009;114:S10–14.
   PubMed Web of Science ®Google Scholar
• Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990;38:203–9.
   PubMed Web of Science ®Google Scholar
• de Bree E, Helm CW. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Rationale and clinical data. Expert Rev Anticancer Ther 2012;12:895–911.
   PubMed Web of Science ®Google Scholar
• Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 2011;37:4–9.
   PubMed Web of Science ®Google Scholar
• Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356–61.
   Web of Science ®Google Scholar
• Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002;128:153–60.
   PubMed Web of Science ®Google Scholar
• Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–53.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Efstathiou E. Peritoneal carcinomatosis 2011. It’s about time for chemosurgery. J BUON 2011;16:400–8.
   PubMed Web of Science ®Google Scholar
• Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21–4.
   PubMed Web of Science ®Google Scholar
• Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–5.
   PubMed Web of Science ®Google Scholar
• Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, Calvert AH. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989;60:767–9.
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389–93.
   PubMed Web of Science ®Google Scholar
• Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, editors Practical gynecologic oncology, 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p 500.
   Google Scholar
• Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004;95:273–80.
   PubMed Web of Science ®Google Scholar
• Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010;6:CD007822.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol 2009;112:265–74.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: A prospective study. J BUON 2011;16:74–9.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al.Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23(suppl12):40–7.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106–15.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–200.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Green S, Hannigan EV, O’Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706–17. Erratum in J Clin Oncol 1992;10:1505.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–5.
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–7.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Comprehensive Cancer Information. Available at www.cancer.gov
   Google Scholar
• Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 2006;100:3–4.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Spirtos NM, Lin WC. Optimal cytoreduction for advanced epithelial ovarian cancer: A commentary. Gynecol Oncol 2006;103:329–35.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up. Gynecol Oncol 2012;127:502–5.
   PubMed Web of Science ®Google Scholar
• Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;73:750–5.
   Web of Science ®Google Scholar
• Morgan Jr RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, et al. National comprehensive cancer networks. Ovarian cancer, version 2. 2013. J Natl Compr Canc Netw Oct 1 2013;11:1199–209.
   PubMed Web of Science ®Google Scholar
• González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, et al. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol 2013;15:509–25.
   PubMed Web of Science ®Google Scholar
• Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, et al. Statement by the Kommission OVAR of the AGO Study Group on the use of HIPEC (hyperthermic intraperitoneal chemotherapy) to treat primary and recurrent ovarian cancer. Geburtshilfe Frauenheilkd 2013;73:221–3.
   PubMed Web of Science ®Google Scholar
• Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 2015;136:130–5.
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234–44.
   PubMed Web of Science ®Google Scholar
• Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012;124:10–14.
   PubMed Web of Science ®Google Scholar
• Spiliotis JD, Rogdakis A, Vaxevanidou A, Datsis A, Zacharis G, Christopoulou A. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. J BUON 2009;14:259–64.
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Mendivil AA, Gray CM, Chapman AP, Stone MK, Tinnerman EJ, Goldstein BH. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma. Int J Hyperthermia 2015;31:396–402.
   PubMed Web of Science ®Google Scholar
• Hayes-Jordan A, Lopez C, Green HL, Xiao LC, Huh W, Herzog CE. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: A novel treatment approach. Pediatr Surg Int 2015.
   PubMed Web of Science ®Google Scholar
• Hayes-Jordan A, Green H, Ludwig J, Anderson P. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer 2012;59:395–7.
   PubMed Web of Science ®Google Scholar
• Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am 2003;12:561–83.
   PubMedGoogle Scholar
• Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol 2014;23:99–106.
   PubMed Web of Science ®Google Scholar
• Ba M, Long H, Zhang X, Tang Y, Wu Y, Yu F, et al. Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. J Cancer Res Clin Oncol 2014;140:1497–506.
   PubMed Web of Science ®Google Scholar
• Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 2009;29:3353–9.
   PubMed Web of Science ®Google Scholar
• Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer 2006;42:589–597.
   PubMed Web of Science ®Google Scholar
• Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: A single institution experience. Ann Surg Oncol 2014;21:1480–6.
   PubMed Web of Science ®Google Scholar
• Vaira M, Robella M, Mellano A, Sottile A, De Simone M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia 2014;30:565–9.
   PubMed Web of Science ®Google Scholar
• Roviello F, Roviello G, Petrioli R, Marrelli D. Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results. Crit Rev Oncol Hematol 2015;95:297–305.
   PubMed Web of Science ®Google Scholar
• Cihoric N, Tsikkinis A, van Rhoon G, Crezee H, Aebersold DM, Bodis S, et al. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. Int J Hyperthermia 2015;31:609–14.
   PubMed Web of Science ®Google Scholar